Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Verapamil
Drug ID BADD_D02348
Description Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina,[L8791] and was the first calcium channel antagonist to be introduced into therapy in the early 1960s.[A188514] It is a member of the non-dihydropyridine class of calcium channel blockers, which includes drugs like [diltiazem] and [flunarizine], but is chemically unrelated to other cardioactive medications.[L8791] Verapamil is administered as a racemic mixture containing equal amounts of the S- and R-enantiomer, each of which is pharmacologically distinct - the S-enantiomer carries approximately 20-fold greater potency than the R-enantiomer, but is metabolized at a higher rate.[A188435]
Indications and Usage For the treatment of hypertension, angina, and cluster headache prophylaxis.
Marketing Status Prescription; Discontinued
ATC Code C08DA01
DrugBank ID DB00661
KEGG ID D02356
MeSH ID D014700
PubChem ID 2520
TTD Drug ID D0R0FE
NDC Product Code 70966-0029
Synonyms Verapamil | Iproveratril | Cordilox | Dexverapamil | Verapamil Hydrochloride | Hydrochloride, Verapamil | Finoptin | Izoptin | Isoptine | Isoptin | Lekoptin | Calan | Falicard
Chemical Information
Molecular Formula C27H38N2O4
CAS Registry Number 52-53-9
SMILES CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Poisoning and toxicityCytochrome P450 2D6P10635T57392Not Available
Sudden cardiac deathPotassium voltage-gated channel subfamily H member 2Q12809T202519927398; 10810773; 10082151; 10408028
Sudden cardiac deathPotassium voltage-gated channel subfamily KQT member 1P51787T495269927398; 10810773; 10082151; 10408028
Sudden cardiac deathSodium channel protein type 5 subunit alphaQ14524T397169927398; 10810773; 10082151; 10408028
Sudden cardiac deathPotassium voltage-gated channel subfamily E member 1P15382Not Available9927398; 10810773; 10082151; 10408028
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cholestasis09.01.01.001--Not Available
Completed suicide08.04.01.010; 19.12.01.0010.002416%Not Available
Confusional state19.13.01.001; 17.02.03.0050.000431%
Constipation07.02.02.001--
Death08.04.01.001--
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Diplopia17.17.01.005; 06.02.06.002--Not Available
Discomfort08.01.08.003--Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.0040.001077%
Drug hypersensitivity10.01.01.0010.001077%Not Available
Dry mouth07.06.01.002--
Dyspepsia07.01.02.001--
Dyspnoea22.02.01.004; 02.01.03.002--
Ear disorder04.03.01.001--Not Available
Ecchymosis24.07.06.002; 23.06.01.001; 01.01.03.001--Not Available
Electrocardiogram abnormal13.14.05.001--Not Available
Electrocardiogram QRS complex prolonged13.14.05.0030.001938%Not Available
Electrocardiogram QT prolonged13.14.05.0040.000393%
Electrolyte imbalance14.05.01.0020.000431%Not Available
Endocarditis11.01.16.001; 02.09.01.0010.000112%
Erythema multiforme23.03.01.003; 10.01.03.015--
Extrapyramidal disorder17.01.02.007--
Fatigue08.01.01.002--
Feeling abnormal08.01.09.0140.000431%Not Available
Feeling cold08.01.09.008--Not Available
Feeling hot08.01.09.0090.000646%Not Available
Flushing08.01.03.025; 24.03.01.002; 23.06.05.003--
Galactorrhoea21.05.02.002; 05.03.04.002--Not Available
Generalised tonic-clonic seizure17.12.01.0020.000861%Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 6 Pages